Valproic AcId for Traumatic BRAin INjury Trial

NCT07166393 — Phase 2 / Phase 3, Not yet recruiting, 432 participants, Northwestern University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Multi-institutional Phase 2/3 Trial of Valproic Acid in Patients With Moderate to Severe Traumatic Brain Injury

RegistryNCT07166393, acronym VIBRANT
StatusNot yet recruiting
PhasePhase 2 / Phase 3
Study typeInterventional; randomized, parallel, masking: triple, treatment
Enrollment432 (Estimated)
SponsorNorthwestern University (Other); collaborators: United States Department of Defense
ConditionsModerate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
InterventionsValproic Acid (VPA), Standard of care treatment + normal saline (Drug, other)
Datesstart 2027-05-01 (estimated), primary completion 2031-05-01 (estimated), completion 2031-12-01 (estimated), first posted 2025-09-10, last updated 2026-08-13
Locations8 sites in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Moderate Traumatic Brain Injury (TBI) All trials for Severe Traumatic Brain Injury All trials of Valproic Acid (VPA) All trials of Standard of care treatment + normal saline

-Summary

The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI).

Patients with moderate to severe TBI will randomly receive either:

1. Standard of care treatment and normal saline
2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose

Expand all sections  ·  Collapse all

+Detailed description

The specific aim is to determine whether giving VPA at either a 50 mg/kg dose or a 100 mg/kg is safe (as measured by adverse events after treatment) in patients with moderate to severe TBI due to brain bruises.

+Arms and interventions

ArmTypeInterventionsDescription
ControlPlacebo comparatorOther: Standard of care treatment + normal salineStandard of Care + Normal Saline (0.9% sodium chloride solution)
ExperimentalExperimentalDrug: Valproic Acid (VPA)Standard of care treatment + one dose of VPA (in 250 ml 0.9% sodium chloride solution) in the following two doses: * Lower dose VPA: 50 mg/kg * Higher dose VPA: 100 mg/kg
  • Valproic Acid (VPA) (Drug): VPA (in 250 ml 0.9% sodium chloride solution)
  • Standard of care treatment + normal saline (Other): Standard of care treatment + normal saline (0.9% sodium chloride solution) vehicle (250 ml)

+Outcome measures

Primary outcomes

  • Extended Glasgow Outcome Scale (GOS-E) [3 months post-injury]: Scoring values range from 1 to 8 with higher scores representing a better outcome. 1 indicates death, 2 indicates a vegetative state, 3 or 4 indicates severe disability, 5 or 6 indicates moderate disability, and 7 or 8 indicates good recovery.

Secondary outcomes

  • Hemorrhagic progression of the contusion (HPC) [First 24 hours post-injury as measured by a CT scan]: We will quantify HPC as the change in volume of the largest contiguous brain lesion in mm. This will be measured through a comparison of the initial and the follow-up CT scan.
  • Disability Rating Score (DRS) [Discharge or day 7 and 3 months post-injury]: This scale includes eight categories: A. Eye opening (0-5), B. Communication ability (0-4), C. Motor response (0-5), D. Feeding - cognitive ability only (0-3), E. Toileting - cognitive ability only (0-3), F. Grooming - cognitive ability only (0-3), G. Level of functioning - physical, mental, emotional or social function (0-5) and H. "Employability" - a full time worker, homemaker, or student (0-3). Higher scores in each category mean a worse outcome.

Other outcomes

  • Disability Rating Score (DRS) [6 months post-injury]: This scale includes eight categories: A. Eye opening (0-5), B. Communication ability (0-4), C. Motor response (0-5), D. Feeding - cognitive ability only (0-3), E. Toileting - cognitive ability only (0-3), F. Grooming - cognitive ability only (0-3), G. Level of functioning - physical, mental, emotional or social function (0-5) and H. "Employability" - a full time worker, homemaker, or student (0-3). Higher scores in each category mean a worse outcome.
  • Extended Glasgow Outcome Scale (GOS-E) [6 months post injury]: Scoring values range from 1 to 8 with higher scores representing a better outcome. 1 indicates death, 2 indicates a vegetative state, 3 or 4 indicates severe disability, 5 or 6 indicates moderate disability, and 7 or 8 indicates good recovery.
  • Glasgow Coma Scale (GCS) [24 hours post-injury]: Evaluates three behavior responses: eye opening, best verbal and best motor. The following scoring is associated with responses: Eye opening response - Spontaneously 4, To speech 3, To pain 2 and No response 1; Best verbal - Oriented to time/place/person 5, Confused 4, Inappropriate words 3, Incomprehensible sounds 2 and No response 1; and Best motor response - Obeys commands 6, Moves to localized pain 5, Flexion withdrawal from pain 4, Abnormal flexion 3, Abnormal extension 2 and No response 1. The scoring is totaled with higher values associated with better response. Total Score: Best response=15, Comatose client=8 or less, and Totally unresponsive=3.

+Eligibility

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

1. Male or female between the ages of 18 and 65 years.
2. Body Mass Index between 18 kg/m2 and 35 kg/m2.
3. Females must be surgically sterilized, postmenopausal, or have a negative urine pregnancy test.
4. Moderate to severe TBI: Glasgow Coma Scale (GCS) 3-12.
5. Cerebral trauma confirmed on the initial CT scan with radiographic findings consistent with Brain Injury Guidelines category 3 (BIG 3) criteria

Exclusion Criteria:

1. Persons with known history of adverse reactions to VPA
2. Persons with known history of hepatitis B or C or clinical history of hepatic dysfunction, pancreatitis, or renal insufficiency.
3. Persons with a known history of thrombocytopenia.
4. Persons with platelet count less than 100,000 per microliter of blood.
5. Persons with 2nd or 3rd degree burns of any size and location.
6. Female subjects who are pregnant or lactating.
7. Persons who are currently incarcerated or are in police custody.
8. Persons with inadequate venous access.
9. Treatment cannot start within 120 minutes from the onset of injury
10. Non-survivable injuries in the estimation of the attending trauma surgeon.
11. Interfacility transfers
12. The time of injury is unknown
13. Patients in hemorrhagic shock with a systolic blood pressure of <90 mmHg on initial evaluation.
14. Persons with a known "do not resuscitate" order prior to randomization
15. Persons with a research "opt out" bracelet
16. Persons who are currently enrolled in another clinical trial.
17. Greater than 90 minutes between the onset of injury and arrival to the hospital

+Locations (8)

FacilityCityCountryStatus
University of Alabama at BirminghamBirmingham, AlabamaUnited States
University of ArizonaTucson, ArizonaUnited States
University of Southern CaliforniaLos Angeles, CaliforniaUnited States
University of California, DavisSacramento, CaliforniaUnited States
Oregon Health & Science UniversityPortland, OregonUnited States
Vanderbilt University Medical CenterNashville, TennesseeUnited States
University of Texas SouthwesternDallas, TexasUnited States
Medical College of WisconsinMilwaukee, WisconsinUnited States

+Publications

  • Results publication: Visa MA, Liggett MR, Lashley S, Bhatti U, Dawood ZA, Anand A, Gill NP, Scholtens DM, Wang B, Alam HB. Valproic acid for treatment of traumatic brain injury: Study protocol for the VIBRANT prospective randomized trial. Transfusion. 2026 May;66 Suppl 1(Suppl 1):S266-S277. doi: 10.1111/trf.70029. Epub 2025 Dec 20. PMID 41420823

+Investigators